C
Codagenix
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for multiple targets
About Codagenix
Codagenix Inc. is a clinical-stage biotechnology company specializing in the development of prophylactic vaccines and oncolytic virus therapies. The company operates in the healthcare and biotechnology markets, focusing on creating live attenuated vaccines and viruses to prevent viral infections and treat solid tumors. Codagenix uses a proprietary synthetic biology platform to recode the genomes of viruses, ensuring that their vaccine candidates are a perfect antigenic match to the target virus. This approach induces a robust immune response to all viral antigens, making their vaccines both safe and effective. The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. Codagenix generates revenue through the development and licensing of its patented vaccine technologies and oncolytic virus therapies. The company's business model is centered around innovation in vaccine design, leveraging its exclusive patents and proprietary technology to maintain a competitive edge in the market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Oyster Bay, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 69.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Vaccines, Infections and Infectious Diseases, Genetics and genomics, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Oct 2023 | $5.9M | — | US Department of War | ↗ |
| SERIES BOther financing | Feb 2023 | $25M | $100M | Serum Institute of India · Euclidean Capital · Adjuvant Capital | ↗ |
Growth signals
Latest recorded traffic for Codagenix is 1.4K monthly website visits, up 27.3% over the last three months. Codagenix's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Small Business Innovation Research
Accelerate Long Island
US Department of War
US Department of Health and Human Services
National Institutes of Health
United States Army Corps of Engineers
Series A3 investors entered at this stage
Adjuvant Capital- ECEuclidean Capital
Serum Institute of India
Other known investors1 additional known investor
Stony Brook University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Codagenix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Codagenix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.